R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
Revenue is up 23% whereas Profit After Tax expands 29% for the company
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopaedics, Neurology, Cardiology, Paediatrics, General Surgery, and Urology
CGHS would give robust coverage to pensioners and with new innovations and practices
Revenue from operations up 26% to Rs. 768 crores
Subscribe To Our Newsletter & Stay Updated
